Form D · Pharmaceuticals

AV Therapeutics, Inc.

New York, NY · CIK 0001537293

Offering snapshot reported May 22, 2014 · SEC filing

Reported sold: $1.26M
Investors reported: 9
Minimum accepted: $0
First sale: Dec 13, 2013

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$660,000 → $1,260,000
Reported investors4 → 9
Minimum accepted$25,000 → $0

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 22, 2014	Amendment	$1,260,000	$600,000vs Dec 30, 2013	9	SEC filing
Dec 30, 2013	Initial	$660,000	No comparison	4	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06b
Duration over one year: No
Business combination: Yes

Sales commissions: $20K (estimated)
Finders' fees: $0
Form D file number: 021-208906

Placement agents were also issued shares of common stock and warrants.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Palladium Capital Advisors, LLC	129400
Objective Equity, LLC	132026

Source: Form D, filed May 22, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Doug Cole	Director
Morton Coleman	Executive
Banerjee Debabrata	Executive
Jan Geliebter	Executive
Abraham Mittelman	Director, Executive
Robert Pollock	Executive
Raj Kumar Tiwari	Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

20 East 68 Th Street
New York, NY, 10065